

immunization information, smoking cessation, oral health, as well as parental depression, domestic violence and substance use counseling. Pediatricians would be asked about the frequency with which they inquire about, use formal screening instruments, treat/manage, and refer patients for various problems/conditions. These various problems/conditions may include maternal depression, parental alcohol/drug use, divorce, illiteracy,

domestic violence exposure, physical or sexual abuse, neglectful parenting, and food and housing insecurity. Findings from the AAP national survey of pediatricians, in conjunction with findings from other data sources and ongoing surveys of home visitors, would inform MCHB's understanding of what is needed to best strengthen the home visitors' and pediatricians' collaborations for at-risk families to support healthy development and to

address the toxic stress and social determinants that drive health and developmental disparities for young children.

**FOR FURTHER INFORMATION CONTACT:**  
Lynn Van Pelt, DMD, Division of Child, Adolescent, and Family Health, Maternal and Child Health Bureau, Health Resources and Services Administration, 5600 Fishers Lane, Room 18W13B, Rockville, Maryland 20857; [lvanpelt@hrsa.gov](mailto:lvanpelt@hrsa.gov).

Grantee/organization name	Grant number	State	FY 2015 authorized funding level	FY 2015 estimated supplemental funding
The American Academy of Pediatrics .....	U04MC07853 .....	IL	\$1,176,800	\$75,000

Dated: September 21, 2015.

**James Macrae,**  
*Acting Administrator.*

[FR Doc. 2015-24395 Filed 9-24-15; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; The Aging and Memory Project.

*Date:* October 26, 2015.

*Time:* 10:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, Suite 2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Kimberly Firth, Ph.D., National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7702, [firthkm@mail.nih.gov](mailto:firthkm@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: September 21, 2015.

**Melanie J. Gray,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-24322 Filed 9-24-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Development of Diagnostic Tests and Kits for Detection of Pathological Angiogenesis in Cancer

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Evaluation Option License Agreement to Angio360 Diagnostics, LLC, a company having a place of business in Wauwatosa, Wisconsin, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/858,068, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed November 9, 2006 (HHS Ref. No.: E-285-2006/0-US-01); US Provisional Patent Application No. 60/879,457, entitled "Organ And Tumor Associated Endothelial Markers," filed January 8, 2007 (HHS Ref. No. E-285-2006/1-US-01); PCT Application No.

PCT/US2007/072395, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 8, 2007 (HHS Ref. No. E-285-2006/2-PCT-01); U.S. Patent Application No. 12/514,297, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed May 8, 2009 (HHS Ref. No. E-285-2006/2-US-02); Australian Patent No. 2007-317753, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref. No. E-285-2006/2-AU-03); Canadian Patent Application No. 2,669,260, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed June 28, 2007 (HHS Ref. No. E-285-2006/2-CA-04); U.S. Patent No.: 8,440,411, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed March 21, 2011 (HHS Ref. No. E-285-2006/2-US-05); U.S. Patent Application No. 13/052,878, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed April 16, 2013 (HHS Ref. No.: E-285-2006/2-US-06); and Australian Application Patent No.: 2014-200453, entitled "Differential Gene Expression in Physiological and Pathological Angiogenesis," filed January 28, 2014 (HHS Ref. No. E-285-2006/2-AU-07). The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Start-Up Exclusive Evaluation Option License Agreement may be worldwide, and the field of use may be limited to "Development of diagnostic tests and kits to determine or monitor pathological angiogenesis related to cancer in animals or humans."